The drug, aducanumab, made by Biogen, would be the first new Alzheimer’s treatment in nearly two decades. But the advisory panel said there was not enough evidence of its effectiveness in slowing cognitive decline.
Banner Sun Health Research Institute: Finger-prick blood test breaks new ground in Alzheimer’s research
Banner Health-led and philanthropy-fueled study enables global research participation Under the leadership of Nicholas Ashton, Ph.D., senior director of the Fluid Biomarker Program at Banner Sun Health Research Institute, an international collaborative effort has...